SGPP2在肺腺癌发生发展中的作用

The Role of SGPP2 in the Occurrence and Development of Lung Adenocarcinoma

摘要: 肺腺癌的靶向治疗在肺腺癌的治疗手段中有着举足轻重的地位，多年来人们一直在致力于寻找新的治疗靶点，鞘氨醇-1-磷酸磷酸酶2 (SGPP2)是一种与血管生成以及肿瘤发生发展密切相关的蛋白，因此本文旨在通过研究探明SGPP2与肺癌的相关性以及潜在治疗靶点的可能性。目的：1) 探究SGPP2在肺腺癌以及配对癌旁组织中的表达差异；2) 揭示SGPP2与肺腺癌的发生发展以及预后的相关性。方法：1) 收集承德医学院附属医院60例肺腺癌手术患者肺癌组织和配对癌旁组织样本，应用免疫组织化学染色技术(IHC)检测SGPP2蛋白的表达差异；2) 系统收集纳入病例的临床病理特征并进行统计学分析。结果：1) 免疫组化结果显示，SGPP2在71.67% (43/60)的肺腺癌组织中为高表达，在28.33% (17/60)的肺腺癌组织种低表达，而癌旁组织中SGPP2蛋白均为低表达(60/60)，分析得到SGPP2基因在肺腺癌组织中表达水平高于癌旁组织(P < 0.05)；2) 在肺腺癌组织中，SGPP2的表达水平与肿瘤直径呈正相关(P < 0.05)。生存曲线分析结果显示SGPP2低表达组的中位无进展生存期(mPFS)显著高于高表达组(P < 0.05)。单因素Cox回归分析显示肺腺癌患者的预后与TNM分期是否为早期以及SGPP2是否高表达关系密切(P < 0.05)，多因素Cox回归分析提示SGPP2的表达水平是肺腺癌患者预后不良的独立危险因素(P < 0.05)。结论：1) SGPP2在肺腺癌组织及其细胞系中的表达水平高于癌旁组织；2) SGPP2的表达水平不仅与肿瘤直径具有相关性，而且是影响肺腺癌患者中位无进展生存期(mPFS)的独立危险因素，SGPP2高表达患者预后更差。

Abstract: Targeted therapy for lung adenocarcinoma holds a crucial position in the treatment methods for lung adenocarcinoma. Over the years, efforts have been made to discover new therapeutic targets. Sphingosine-1-phosphate phosphatase 2 (SGPP2) is a protein closely related to angiogenesis and tumor occurrence and development. Therefore, this study aims to explore the correlation between SGPP2 and lung adenocarcinoma as well as the possibility of potential therapeutic targets. Objective: 1) To investigate the expression differences of SGPP2 in lung adenocarcinoma and paired adjacent tissues; 2) To reveal the correlation between SGPP2 and the occurrence, development, and prognosis of lung adenocarcinoma. Methods: 1) 60 surgical patients with lung adenocarcinoma from the Affiliated Hospital of Chengde Medical University and their paired adjacent tissues were collected. The expression difference of SGPP2 protein was detected by immunohistochemical staining (IHC); 2) The clinical pathological characteristics of the included cases were systematically collected and statistically analyzed. Results: 1) The immunohistochemical results showed that SGPP2 was highly expressed in 71.67% (43/60) of lung adenocarcinoma tissues, and lowly expressed in 28.33% (17/60) of lung adenocarcinoma tissues. In contrast, the SGPP2 protein was all lowly expressed in the adjacent tissues (60/60). The analysis revealed that the expression level of the SGPP2 gene in lung adenocarcinoma tissues was higher than that in adjacent tissues (P < 0.05); 2) In lung adenocarcinoma tissues, the expression level of SGPP2 was positively correlated with tumor diameter (P < 0.05). The survival curve analysis showed that the median progression-free survival (mPFS) of the low-expression group of SGPP2 was significantly higher than that of the high-expression group (P < 0.05). Univariate Cox regression analysis showed that the prognosis of lung adenocarcinoma patients was closely related to whether the TNM stage was early and whether SGPP2 was highly expressed (P < 0.05). Multivariate Cox regression analysis suggested that the expression level of SGPP2 was an independent risk factor for poor prognosis in lung adenocarcinoma patients (P < 0.05). Conclusion: 1) The expression level of SGPP2 in lung adenocarcinoma tissues and cell lines is higher than that in adjacent tissues; 2) The expression level of SGPP2 is not only correlated with tumor diameter, but also an independent risk factor affecting the median progression-free survival (mPFS) of lung adenocarcinoma patients. Patients with high SGPP2 expression have a worse prognosis.